Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Recent Articles in CRO/CMO Services

MicroConstants China to Manage Clinical Research Center at #307 Hospital
Jan 29, 2013
MicroConstants China, a Beijing CRO that offers preclinical pharmacokinetic studies, early-stage clinical trials, and regulated bioanalysis, signed a strategic collaboration agreement to manage the clinical research center of the No. 307 Hospital of the People’s Liberation Army. The parent of MicroConstants China is headquartered in San Diego. More details....

Share this with colleagues:  

Can-Fite Biopharma Shifts Drug Manufacturing to China
Jan 21, 2013
Can-Fite Biopharma, an Israeli firm developing drugs for inflammatory and liver disease, will transfer its drug production to China. The company said China’s Chemspec has optimized production of its APIs, reducing its costs considerably. Can-Fite is facing multiple Phase III clinical trials for its drug candidates, and it estimates that outsourcing the manufacturing to Chemspec will save the company millions of dollars. More details....

Stock Symbols: (TASE: CFBI; OTCBB: CANFY)

Share this with colleagues:  

HitGen and Viva Biotech Team Up to Provide Early-Stage CRO Services
Dec 24, 2012
HitGen Ltd. and Viva Biotech Ltd., two China CROs specializing in early-stage services, announced a new collaboration. HitGen, located in Chengdu, offers lead generation services. VivaBiotech of Shanghai is a structure-based drug discovery CRO. According to the two companies, their now-integrated early hit-to lead generation program addresses a previously unmet need in China’s pre-clinical drug discovery sector. More details....

Share this with colleagues:  

ShangPharma Accepts $9/ADS Go-Private Offer
Dec 21, 2012
ShangPharma, a pre-clinical CRO headquartered in Shanghai’s Zhangjiang Hi-Tech Park, has agreed to a go-private offer of $9.00 per ADS. The offer was made by a group comprised of Michael Xin Hui, the company’s Chairman/CEO/Founder, and TPG, a US private equity group that has long been an investor in ShangPharma. Mr. Hui currently controls 54% of the company’s shares, while TPG still owns 11%. TPG will presumably fund at least some of the purchase of the remaining 35% of outstanding shares. The deal values ShangPharma at $173 million. More details....

Stock Symbol: (NYSE: SHP)

Share this with colleagues:  

Innovent Constructing Biologic Facility in Suzhou
Nov 1, 2012
Innovent Biologics, a Suzhou company formed last year, is building a biotech plant in BioBay. The company has two aims: it intends to in-license biotech drugs for the China market, and it also wants to provide contract manufacturing services to other companies. The company is led by an international management team of experienced biotech executives. With $30 million in startup capital from Fidelity, Lilly Ventures and Suzhou BioBay, Innovent has instant credibility. More details....

Share this with colleagues:  

More Articles >>
Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here